These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1676252)

  • 1. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.
    Yarchoan R; Venzon DJ; Pluda JM; Lietzau J; Wyvill KM; Tsiatis AA; Steinberg SM; Broder S
    Ann Intern Med; 1991 Aug; 115(3):184-9. PubMed ID: 1676252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive CD4 cell depletion and death in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Moyle G; Gazzard BG
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):927-9. PubMed ID: 8100272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection.
    Nightingale SD; Jockusch JD; Haslund I; Cal SX; Peterson DM; Loss SD
    Arch Intern Med; 1993 Jun; 153(11):1313-8. PubMed ID: 8099477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
    JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy.
    Pluda JM; Yarchoan R; Jaffe ES; Feuerstein IM; Solomon D; Steinberg SM; Wyvill KM; Raubitschek A; Katz D; Broder S
    Ann Intern Med; 1990 Aug; 113(4):276-82. PubMed ID: 1973886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3.
    Spino C; Kahn JO; Dolin R; Phair JP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):346-55. PubMed ID: 9342254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
    Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos AI; Katzenstein T; van Lunzen J; Antunes F; Phillips AN; Lundgren JD
    Ann Intern Med; 1999 Apr; 130(7):570-7. PubMed ID: 10189326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
    Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
    Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ lymphocyte counts and the risk of death in advanced HIV infection.
    Schlumpberger JM; Wolde-Tsadik G; Yao JF; Hara J
    J Fam Pract; 1994 Jan; 38(1):33-8. PubMed ID: 8289049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group.
    Vella S; Giuliano M; Dally LG; Agresti MG; Tomino C; Floridia M; Chiesi A; Fragola V; Moroni M; Piazza M
    J Acquir Immune Defic Syndr (1988); 1994 Jan; 7(1):31-8. PubMed ID: 7903380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.